Home

desinfizieren Kritisch Geh hinauf ivig treatment for kawasaki disease Adler Exquisit Froh

Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High‐Risk Patients With Kawasaki Disease | Journal of the American Heart Association
Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High‐Risk Patients With Kawasaki Disease | Journal of the American Heart Association

Diagnostics | Free Full-Text | Intravenous Immunoglobulin in Kawasaki Disease—Evolution and Pathogenic Mechanisms
Diagnostics | Free Full-Text | Intravenous Immunoglobulin in Kawasaki Disease—Evolution and Pathogenic Mechanisms

Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease | Scientific Reports
Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease | Scientific Reports

The Lancet - Kawasaki disease is a self-limited vasculitis that is the most common cause of acquired heart disease in children in developed countries. Although intravenous immunoglobulin (IVIG) is effective therapy, 10–20%
The Lancet - Kawasaki disease is a self-limited vasculitis that is the most common cause of acquired heart disease in children in developed countries. Although intravenous immunoglobulin (IVIG) is effective therapy, 10–20%

IVIG Treatment for Kawasaki Disease | AmeriPharma™ Specialty
IVIG Treatment for Kawasaki Disease | AmeriPharma™ Specialty

Kawasaki Disease: An Update on Diagnosis and Treatment - ScienceDirect
Kawasaki Disease: An Update on Diagnosis and Treatment - ScienceDirect

Understanding Kawasaki Disease
Understanding Kawasaki Disease

Clinical Practice Guidelines : Kawasaki disease
Clinical Practice Guidelines : Kawasaki disease

Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial - The Lancet Child & Adolescent Health
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial - The Lancet Child & Adolescent Health

Management of Kawasaki disease | Archives of Disease in Childhood
Management of Kawasaki disease | Archives of Disease in Childhood

Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease | Semantic Scholar
Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease | Semantic Scholar

IJMS | Free Full-Text | Anemia in Kawasaki Disease: Hepcidin as a Potential Biomarker
IJMS | Free Full-Text | Anemia in Kawasaki Disease: Hepcidin as a Potential Biomarker

Clinical characteristics in Kawasaki disease related to intravenous... | Download Table
Clinical characteristics in Kawasaki disease related to intravenous... | Download Table

Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease | Italian Journal of Pediatrics | Full Text
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease | Italian Journal of Pediatrics | Full Text

An Overview of Kawasaki Disease
An Overview of Kawasaki Disease

Heart Rate, Responsiveness to Intravenous Immunoglobulin, and Coronary Artery Aneurysms in Kawasaki Disease - The Journal of Pediatrics
Heart Rate, Responsiveness to Intravenous Immunoglobulin, and Coronary Artery Aneurysms in Kawasaki Disease - The Journal of Pediatrics

Treat acute Kawasaki disease with aspirin plus intravenous immunoglobulin to improve coronary outcomes | SpringerLink
Treat acute Kawasaki disease with aspirin plus intravenous immunoglobulin to improve coronary outcomes | SpringerLink

Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study - The Lancet Child & Adolescent Health
Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study - The Lancet Child & Adolescent Health

Treatment Options for Refractory Kawasaki Disease
Treatment Options for Refractory Kawasaki Disease

Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin | Semantic Scholar
Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin | Semantic Scholar

Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks | Italian Journal of Pediatrics | Full Text
Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks | Italian Journal of Pediatrics | Full Text

Figure 1 | Archives of Disease in Childhood
Figure 1 | Archives of Disease in Childhood

Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials - eBioMedicine
Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials - eBioMedicine

Various adjuncts to IVIg help treat coronary artery abnormalities in pediatric Kawasaki disease | MDedge Pediatrics
Various adjuncts to IVIg help treat coronary artery abnormalities in pediatric Kawasaki disease | MDedge Pediatrics

Kawasaki Kids on X: "Day 4 of Kawasaki Disease Awareness Month IVIG Treatment for Kawasaki Disease is the most widely used treatment to stop the fever and inflammation in the child's body.
Kawasaki Kids on X: "Day 4 of Kawasaki Disease Awareness Month IVIG Treatment for Kawasaki Disease is the most widely used treatment to stop the fever and inflammation in the child's body.